News ArticleSun Pharmaceutical Posts Rs 8,712.9 Million Profit in Q2 FY2026-27 with Revenue Rs 61,419.2 Million
Company reports unaudited standalone financial results for quarter and half year ended 30 September 2026, including Rs 315.3 million exceptional item
Sun Pharmaceutical Industries Limited announced its unaudited standalone financial results for the quarter and half year ended 30 September 2026, reporting Rs 8,712.9 million profit for the quarter and total revenue from operations of Rs 61,419.2 million. The results include an exceptional item of Rs 315.3 million and EPS of Rs 3.6 per share for Q2 2026-27.
Sun Pharmaceutical Industries Limited
Financial Results
Sun Pharmaceutical Industries Limited announced its unaudited standalone financial results for the quarter and half year ended 30 September 2026, posting a net profit of Rs 8,712.9 million for the quarter on total revenue of Rs 61,419.2 million from operations. The results include an exceptional item of Rs 315.3 million.
The total revenue from operations for Q2 FY2026-27 was Rs 61,419.2 million, comprising Rs 60,565.9 million from contracts with customers and Rs 853.3 million from other operating revenues.
Total income including other income was Rs 62,229.3 million, with other income at Rs 810.1 million.
Expenses totaled Rs 50,199.4 million, including costs of materials consumed (Rs 16,604.4 million), employee benefits (Rs 8,520.0 million), finance costs (Rs 2,769.6 million), depreciation and amortization expense (Rs 3,157.9 million), and other operating expenses (Rs 19,984.1 million).
The profit before exceptional items and tax was Rs 12,029.9 million, with an exceptional item of Rs 315.3 million recorded during the quarter.
Tax expenses amounted to Rs 3,317.0 million for the quarter with an exceptional tax credit of Rs 79.3 million relating to the exceptional item, resulting in net profit of Rs 8,712.9 million for the quarter ended 30 September 2026, and earnings per share of Rs 3.6 (basic and diluted).
Highlights
- Quarterly revenue from operations reached Rs 61,419.2 million for Q2 2026-27.
- Net profit after tax for Q2 was Rs 8,712.9 million, with an EPS of Rs 3.6 per share.
- Exceptional item expense of Rs 315.3 million included in results.
- Total expenses for the quarter were Rs 50,199.4 million, including Rs 16,604.4 million on materials consumed.
- Half year ended 30 September 2026 net profit was Rs 19,864.3 million with revenue Rs 118,830.5 million.
Key Data Snapshot
What happened
- Sun Pharmaceutical approved its unaudited standalone financial results for the quarter and half year ended 30 September 2026.
- The company reported a net profit of Rs 8,712.9 million for Q2 FY2026-27.
- Revenue from operations for the quarter reached Rs 61,419.2 million.
- The results included an exceptional item amounting to Rs 315.3 million.
- Earnings per share (basic and diluted) for the quarter stood at Rs 3.6.
Key details
- Total income including other income was Rs 62,229.3 million for Q2 FY2026-27.
- Expenses included cost of materials Rs 16,604.4 million, employee benefits Rs 8,520.0 million, finance costs Rs 2,769.6 million, and depreciation Rs 3,157.9 million.
- Tax expense for the quarter was Rs 3,317.0 million plus an exceptional tax credit of Rs 79.3 million.
- Half year ended 30 September 2026 saw net profit of Rs 19,864.3 million and revenue of Rs 118,830.5 million.
Regulatory and governance context
- Results were approved by the Board of Directors at meeting held on 30 October 2026.
- The financial results were subject to limited review by the statutory auditors SR BC & CO LLP.
- The company complied with SEBI Listing Regulations including Regulations 30 and 33.
- The results were prepared under Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting".
Highlights
- Quarterly revenue from operations reached Rs 61,419.2 million for Q2 2026-27.
- Net profit after tax for Q2 was Rs 8,712.9 million, with an EPS of Rs 3.6 per share.
- Exceptional item expense of Rs 315.3 million included in results.
- Total expenses for the quarter were Rs 50,199.4 million, including Rs 16,604.4 million on materials consumed.
- Half year ended 30 September 2026 net profit was Rs 19,864.3 million with revenue Rs 118,830.5 million.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulations 30 and 33
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Navin Fluorine International Ltd Reports ₹269.24 Crore Q2 Profit and Declares ₹8 Interim Dividend for FY2026-27
Navin Fluorine International Limited released its unaudited consolidated financial results for the quarter and half year ended September 30, 2026. The company recorded a profit after tax of ₹269.24 crore for the quarter and declared an interim dividend of ₹8 per equity share for the fiscal year 2026-27.
Read Full Story
Max Healthcare Announces Q2 FY2027 Results and ₹190 Crore Expansion for Noida and Vaishali Hospitals
Max Healthcare Institute Limited approved its unaudited financial results for the quarter and half year ended September 30, 2026, and sanctioned ₹93 crore and ₹97 crore capital expenditure for upgrading hospitals at Noida and Vaishali, respectively. The company also revised the Gurugram hospital project's cost to ₹1,143 crore with a new completion timeline of April 2027.
Read Full Story
GAIL India Reports ₹11,611.44 Crore Profit Before Tax for First Half of 2026
GAIL (India) Limited posted a profit before tax of ₹11,611.44 crore for the half year ended September 30, 2026, with total income of ₹86,116.52 crore, reflecting its continuing scale of operations. The company released its unaudited standalone financial results, which include ongoing legal matters contested with the Petroleum and Natural Gas Regulatory Board and central excise authorities.
Read Full Story
